Daniel Ek's health-scanning startup Neko Health will open its first American office on September 24 in SoHo at 300 Lafayette Street in Manhattan, betting that affluent New Yorkers will pay for proprietary body-scanning technology paired with bloodwork and fitness data analysis. The company has already attracted more than 25,000 New Yorkers to its waitlist before the doors even open.
Neko Health's entry into the U.S. market represents a significant moment for the private health-tech sector. The startup raised $700 million in Series C funding last month, signaling robust investor confidence in premium consumer health services that operate largely outside traditional healthcare infrastructure. The company already serves customers in the U.K. and Sweden, where it has scanned more than 100,000 people.
Private Capital Fueling Health Innovation
Spotify co-founder Ek and CEO Hjalmar Nilsonne have tapped into a growing appetite among venture capitalists for health-scanning ventures created by tech entrepreneurs. The sector reflects a broader market trend: affluent consumers increasingly prefer direct-to-consumer health monitoring over waiting for traditional medical appointments. These companies operate on a subscription or pay-per-scan model, removing the bureaucratic friction of insurance-dependent healthcare.
Neko isn't alone in this space. Midjourney, the AI lab known for its image generation platform, is developing its own body scanner for integration into a spa experience, with plans to open in San Francisco in 2027. Tony Robbins and Peter Diamandis launched Fountain Life, which offers scans and health assessments. Function Health, co-founded by wellness podcaster Dr. Mark Hyman, has expanded its blood-testing service after acquiring Ezra, a body-scanning startup, and recently secured $450 million in funding from General Catalyst's Customer Value Fund through a profit-sharing loan arrangement.
Market-Driven Competition
The profit-sharing model used by General Catalyst shows how private capital structures incentives differently than traditional venture equity. Companies like Function Health repay loans through revenue sharing rather than fixed interest, aligning investor returns with actual business performance. This mechanism forces companies to achieve profitability—a discipline that government-funded healthcare programs don't face.
Neko Health's $700 million Series C demonstrates investor conviction that consumers will pay directly for preventive health scanning without waiting for insurance approvals or physician referrals. The 25,000-person waitlist in New York alone suggests genuine demand, not artificial scarcity. These numbers matter because they show market validation independent of government mandates or subsidies.
The startup's technology combines body scanning with external data—bloodwork results and fitness tracker information—to create a comprehensive health profile. This integration of multiple data sources represents the kind of innovation that thrives when companies compete for customer dollars rather than government contracts.
Why This Matters:
Neko Health's U.S. expansion illustrates how private markets solve problems faster than government healthcare systems. Consumers dissatisfied with traditional medicine's appointment delays and insurance friction are voting with their wallets for premium alternatives. The $700 million Series C and the emergence of competing health-scanning companies show that venture capital recognizes genuine demand. These companies operate without government subsidies, regulatory mandates, or insurance bureaucracy—they succeed or fail based on whether customers believe they're worth paying for. The 25,000-person waitlist in New York alone demonstrates real market demand, not manufactured demand. As these companies scale and compete, they'll likely drive down prices and improve technology through market pressure, the mechanism that has consistently outpaced government healthcare innovation. Whether Neko Health and its competitors ultimately disrupt traditional preventive care depends on their ability to deliver results that justify their costs—a test that government programs rarely face.